



ICF Selected for \$120 Million USAID Infectious Disease Detection and Surveillance Project

July 30, 2018

ICF Key Partner in Helping Advance Global Health Systems

FAIRFAX, Va., July 30, 2018 /PRNewswire/ -- The U.S. Agency for International Development (USAID) recently selected global consulting and digital services provider ICF (NASDAQ: ICFI) for a new task order to provide infectious disease detection and surveillance support to affected lower and middle income countries worldwide.

The task order was awarded by the Bureau for Global Health, Office of Infectious Disease under the U.S. General Services Administration's OASIS (One Acquisition Solution for Integrated Services) indefinite delivery, indefinite quantity contract. It has a ceiling value of \$120 million and a term of five years including one base year and four option years.

ICF will provide direct implementation support services and capacity building assistance to countries to develop or improve their national diagnostic networks, laboratory systems and surveillance mechanisms so they are better able to detect and monitor the ever-growing number of emerging and re-emerging infectious diseases. As demonstrated by recent outbreaks of Ebola and multidrug-resistant tuberculosis, these diseases can have a devastating impact on populations and quickly cross geographical borders.

"We are excited about this opportunity to work in partnership with USAID and focal countries to strengthen diagnostic networks, surveillance systems and capacity to detect anti-microbial resistance," said Leo Ryan, senior vice president for ICF. "This project will draw on our extensive expertise in building country capacity to collect and utilize health data, strengthen national and local health information systems and address infectious disease challenges. It also leverages the deep experience of our key consortium partners."

ICF has a long history of supporting USAID programs that measurably improve the health of communities around the world, and has demonstrated expertise managing large, complex, integrated projects. With this contract, ICF will strengthen its partnership with USAID in helping it meet its vision of providing high-quality, specific technical assistance and support to countries to enable them to rapidly detect new and emerging infectious diseases and pathogens.

This project will also be an important mechanism to support USAID's partnership within the U.S. government to advance the Global Health Security Agenda, a worldwide effort to help build countries' capacity to help create a world safe and secure from infectious disease threats and elevate global health security as a national and global priority.

Read more about ICF's [global health](#) and [disease surveillance](#) services.

About ICF

ICF (NASDAQ:ICFI) is a global consulting services company with over 5,000 specialized experts, but we are not your typical consultants. At ICF, business analysts and policy specialists work together with digital strategists, data scientists and creatives. We combine unmatched industry expertise with cutting-edge engagement capabilities to help organizations solve their most complex challenges. Since 1969, public and private sector clients have worked with ICF to navigate change and shape the future. Learn more at [icf.com](#).

Caution Concerning Forward-looking Statements

Statements that are not historical facts and involve known and unknown risks and uncertainties are "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. Such statements may concern our current expectations about our future results, plans, operations and prospects and involve certain risks, including those related to the government contracting industry generally; our particular business, including our dependence on contracts with U.S. federal government agencies; and our ability to acquire and successfully integrate businesses. These and other factors that could cause our actual results to differ from those indicated in forward-looking statements are included in the "Risk Factors" section of our securities filings with the Securities and Exchange Commission. The forward-looking statements included herein are only made as of the date hereof, and we specifically disclaim any obligation to update these statements in the future.

Contact: Lauren Dyke, lauren.dyke@ICF.com, +1.571.373.5577

 View original content with multimedia: <http://www.prnewswire.com/news-releases/icf-selected-for-120-million-usaid-infectious-disease-detection-and-surveillance-project-300688549.html>

SOURCE ICF